Trethera News
June 3, 2025
Los Angeles, June 3, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA)....
May 21, 2025
Los Angeles, May 21, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will...
April 22, 2025
Los Angeles, April 22, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summit...
March 31, 2025
Los Angeles, March 31, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lou...
February 25, 2025
Los Angeles, February 25, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced research results in the peer-reviewed journal Immunology demonstrating that TRE-515 selectively...